26th week of 2022 patent applcation highlights part 27 |
Patent application number | Title | Published |
20220204522 | PROCESS FOR SEPARATING AND PURIFYING ARTEMISININ - The present invention belongs to a process for separating and purifying artemisinin comprising S1. concentrating and pressure filtering an artemisinin extraction liquid to obtain a crude artemisinin crystal 1 and a mother liquor 1, and concentrating the mother liquor 1 to obtain an artemisinin extract 1; S2. adding the artemisinin extract 1 to an aqueous alcohol solution to obtain an aqueous alcohol extraction liquid 1 and an artemisinin extract 2; S3. subjecting the artemisinin extract 2 to S2 so as to obtain an aqueous alcohol extraction liquid 2 and an artemisinin extract 3; S4. combining the aqueous alcohol extraction liquids 1 and 2 to obtain a crude artemisinin crystal 2 and a mother liquor 2; and S5. combining the crude artemisinin crystals 1 and 2, then dissolving same in an alcohol solvent and filtering same, heating the filtrate and then concentrating same to obtain a fine artemisinin product. | 2022-06-30 |
20220204523 | INTERMEDIATE OF ERIBULIN AND SYNTHESIS METHOD AND USE THEREOF - An intermediate compound is prepared and used for the synthesis of halichondrin B, eribulin or an analog thereof, particularly a structural fragment C27-C35 thereof. The starting materials of the synthetic route are readily available, and the optical purity of the starting materials can be ensured, so that the optical purity of the structural fragment C27-C35 in halichondrin B, eribulin or the analog thereof is ensured. Steps for constructing a chiral center of the structural fragment C27-C35 feature higher diastereoselectivity and yield, in particular preparation methods of compounds of formulae (X), (XI), (XVI) and (XV). By-products of partial reactions can be removed only by recrystallization, which results in easy purification and significant reduce in cost. | 2022-06-30 |
20220204524 | GINKGOLIDE B DERIVATIVE AND SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to the technical field of medicine, and to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of Ginkgolide B by means of a hydroxyl group at the 10-position and ester derivatives of carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts. Ginkgolide B is used as a parent body and is prepared by means of chemical structure modification so as to achieve the goals of improving solubility, increasing bioavailability and enhancing healing efficacy. The prepared compound and carboxylate salts thereof have significant platelet activating factor antagonism, an anticoagulant effect and an anti-acute cerebral ischemia effect, and can be used for preparing a drug for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, as well as inflammation, asthma and other diseases related to a platelet activating factor. | 2022-06-30 |
20220204525 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES - The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrirnidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like. | 2022-06-30 |
20220204526 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS - The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof. | 2022-06-30 |
20220204527 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS - The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders. | 2022-06-30 |
20220204528 | DISCOVERY OF IMIDAZOTHIAZOLE- AND IMIDAZOOXAZOLE-BASED SELECTIVE HER4 KINASE INHIBITORS AS POTENTIAL ANTICANCER AGENTS - Novel first-in-class imidazothiazole- and imidazooxazole-based potent and selective HER4 kinase inhibitors for therapeutic formulations and methods for treating cancer. | 2022-06-30 |
20220204529 | METHOD FOR PREPARING LORNOXICAM - The present disclosure relates to the technical field of drug synthesis, in particular to a method for preparing lornoxicam. The method includes the following steps: using 6-chloro-4-hydroxy-2-methyl-2-H-thieno[2,3-e]-1,2-thiazine methyl carboxylate-1,1-dioxide and 2-aminopyridine as raw materials, and xylene as a solvent; mixing the raw material and solvent, and adding a stabilizer, to obtain a mixture; subjecting the mixture to an ammonolysis; cooling the resulting reactant; conducting a vacuum concentration to remove the solvent; adding an organic solvent and slurrying, and filtering, to obtain a crude lornoxicam; and refining the crude lornoxicam to obtain the lornoxicam. In the present disclosure, p-toluenesulfonic acid is used as a stabilizer to reduce the reaction temperature and promote the reaction to proceed forward, thereby improving the quality and yield of the product. | 2022-06-30 |
20220204530 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF - The inventive compounds are small molecule therapeutics that are potent inhibitors of arginase 1 and arginase 2 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity. | 2022-06-30 |
20220204531 | DIBORONIC ACID COMPOUNDS AND METHODS OF MAKING AND USING THEREOF - Disclosed are diboronic acid compounds and diboronic acid compound-based sensors for glucose detection, as well as methods for glucose testing in a sample. The diboronic acid compounds allow for selective detection of glucose in the presence of interference sugars, long-term stability, and ease of preparation. Sensors containing the disclosed diboronic acid compounds allow for selective detection of glucose with improved stability at a low cost. | 2022-06-30 |
20220204532 | EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME - The present disclosure relates to an emitting compound and organic light emitting device including the same, and more specifically, relates to an emitting compound of following and an organic light emitting diode and an organic light emitting device each including the emitting compound. | 2022-06-30 |
20220204533 | Organic Borate-Based Catalyst, Method For Preparing Isobutene Oligomer Using The Same And Isobutene Oligomer Prepared Thereby - The present invention relates to an organic borate-based catalyst including a compound represented by the following Formula 1 and a hydroxyl group-containing compound, a method for preparing an isobutene oligomer using the same and an isobutene oligomer prepared thereby: | 2022-06-30 |
20220204534 | APPARATUS AND CONTINUOUS FLOW PROCESS FOR PRODUCTION OF BORONIC ACID DERIVATIVE - A process for a continuous production of a boronic acid derivative and an apparatus of performing the process are disclosed. | 2022-06-30 |
20220204535 | COMPOSITION, FILM, METHOD OF FORMING FILM, METHOD OF FORMING PATTERN, METHOD OF FORMING ORGANIC-UNDERLAYER-FILM REVERSE PATTERN, AND METHOD OF PRODUCING COMPOSITION - A composition includes: a metal compound including a ligand; and a solvent. The ligand is derived from a compound represented by formula (1). L represents an oxygen atom or a single bond; R | 2022-06-30 |
20220204536 | CRYSTALS - Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals. | 2022-06-30 |
20220204537 | OPTICALLY ACTIVE BISPHOSPHINOMETHANE, METHOD FOR PRODUCING THE SAME, AND TRANSITION METAL COMPLEX AND ASYMMETRIC CATALYST - There is provided a novel optically active bisphosphinomethane useful as a ligand for an asymmetric catalyst, excellent in oxidation resistance in air, and easy in handling. There is also provided a transition metal complex using the optically active bisphosphinoraethane having excellent asymmetric catalytic ability as a ligand. The optically active bisphosphinomethane is represented by the general formula (1), and the transition metal complex has the optically active bisphosphinomethane as a ligand. | 2022-06-30 |
20220204538 | ANTI-CANCER GOLD COMPOUNDS - A compound according to Formula (I), or a pharmaceutically acceptable salt thereof: | 2022-06-30 |
20220204539 | CD73 INHIBITORS - The present disclosure relates generally to compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided. | 2022-06-30 |
20220204540 | ESTERS OF NON- AROMATIC HETEROCYCLIC COMPOUNDS HAVING A NEMATOCIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF - Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described. | 2022-06-30 |
20220204541 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS - There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. | 2022-06-30 |
20220204542 | SHARED MEMORY FOR INTELLIGENT NETWORK INTERFACE CARDS - In an example, there is disclosed a host-fabric interface (HFI), including: an interconnect interface to communicatively couple the HFI to an interconnect; a network interface to communicatively couple the HFI to a network; network interface logic to provide communication between the interconnect and the network; a coprocessor configured to provide an offloaded function for the network; a memory; and a caching agent configured to: designate a region of the memory as a shared memory between the HFI and a core communicatively coupled to the HFI via the interconnect; receive a memory operation directed to the shared memory; and issue a memory instruction to the memory according to the memory operation. | 2022-06-30 |
20220204543 | ORGANIC ACID SALT OF NICOTINAMIDE RIBOSIDE, COMPOSITION INCLUDING ORGANIC ACID SALT, AND PREPARATION METHODS OF ORGANIC ACID SALT AND COMPOSITION - An organic acid salt of nicotinamide riboside (NR) is provided, where an organic acid is selected from the group consisting of malic acid, citric acid, royal jelly acid, and the like, and a molar ratio of the NR to the organic acid is 1:2 or 1:1. A compound composition of an organic acid salt of NR and a carrier is further provided, where the carrier is selected from the group consisting of niacin, glutamic acid, royal jelly acid, nervonic acid, microcrystalline cellulose (MCC), and apple cider vinegar powder. The present disclosure adopts an organic acid with strong acidity, and such an organic acid can form an intimate ion pair with NR and show some hydrophobicity, which improves the stability of NR. The carrier can prevent moisture penetration and improve the water resistance of the organic acid salt. | 2022-06-30 |
20220204544 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS - This disclosure provides electrochemically-cleavable linkers with cleavage potentials that are less than the redox potential of the solvent in which the linkers are used. In some applications, the solvent may be water or an aqueous buffer solution. The linkers may be used to link a nucleotide to a bound group. The linkers include a cleavable group which may be one of a methoxybenzyl alcohol, an ester, a propargyl thioether, or a trichloroethyl ether. The linkers may be cleaved in solvent by generating an electrode potential that is less than the redox potential of the solvent. In some implementations, an electrode array may be used to generate localized electrode potentials which selectively cleave linkers bound to the activated electrode. Uses for the linkers include attachment of blocking groups to nucleotides in enzymatic oligonucleotide synthesis. | 2022-06-30 |
20220204545 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS - The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2022-06-30 |
20220204546 | METHOD FOR PREPARING 7ALPHA-METHYL-19-ALDEHYDE-4-ANDROSTENE-3,17-DIONE BY ELECTROCATALYTIC OXIDATION - The present invention relates to a method for preparing 7α-methyl-19-aldehyde-4-androstene-3,17-dione by electrocatalytic oxidation. The method specifically includes: adopting an H-shaped electrolytic cell for reaction, in an anode chamber, using a metal oxide catalyst as a working electrode, using 7α-methyl-17,19-dihydroxy-4-androstene-3-one as a reaction substrate, and dissolving it in a mixed solvent to be used as an anolyte, and adding nitroxide radicals to be used as a medium; and in a cathode chamber, using a platinum sheet as a counter electrode, using a weakly alkaline solution as a catholyte, carrying out an electrocatalytic oxidation reaction in a constant temperature water bath, adding an organic solvent at the end of the reaction for extraction to obtain an organic extract liquor, and taking an organic layer and carrying out distilling under a reduced pressure to obtain 7α-methyl-19-aldehyde-4-androstene-3,17-dione. | 2022-06-30 |
20220204547 | NOVEL METHOD FOR SYNTHESIZING 25-OH CHOLESTEROL/CALCIFEDIOL FROM PHYTOSTEROL - The present invention discloses novel method for synthesizing vegan 25-OH cholesterol/Calcifediol from inexpensive crude phytosterol. According to the method, Phytosterols are reacted to form corresponding i-steroid through tosylation and methanolysis. i-steroid on reductive ozonolysis to C-22 alcohol and conversion via C-22 tosylate to C-22 iodide in good yield. Coupling of C-22 tosylate with Grignard reagent of 4-bromo-2-methyl-2-[(trimethylsilyl)oxy]butane followed by deprotection yielded 25-OH cholesterol. In a process variant, nickel mediated conjugate addition of C-22 iodide to an electron deficient alkene ethyl acrylate and treating corresponding ester with methyl magnesium bromide as means of installing the side chain of 25-OH cholesterol in high yield. Further bromination reaction of 25-OH cholesterol diacetate followed by dehydrobromination using TBAF yielded 25-OH 7-dehydrocholesterol. Further photo reaction of 25-OH 7-dehydrocholesterol in to previtamin D3 using high or medium pressure mercury lamp and subsequent thermal reaction of previtamin D3 to 25-OH vitamin D3 (Calcifediol) in good yield. | 2022-06-30 |
20220204548 | SMALL MOLECULE MODULATORS OF GUT BACTERIAL BILE ACID METABOLISM - Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII). | 2022-06-30 |
20220204549 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS - The methods described herein provide a means of producing an array of spatially separated proteins. The method relies on covalently attaching each protein of the plurality of proteins to a structured nucleic acid particle (SNAP), and attaching the SNAPs to a solid support. | 2022-06-30 |
20220204550 | METHOD FOR PRODUCING PEPTIDE COMPOUND - The invention provides a method for producing a peptide which includes a step of reacting a peptide in which a C-terminal carboxy group is activated which is obtained by reacting an N-protected peptide represented by the formula (I): | 2022-06-30 |
20220204551 | METHOD FOR THE PURIFICATION OF LIPOGLYCOPEPTIDE ANTIBIOTICS - Method for purifying at least one lipoglycopeptide antibiotic comprising the steps of: i) dissolving said at least one lipoglycopeptide antibiotic in an aqueous solution to form a mixture, ii) loading said mixture into a chromatographic column comprising a stationary phase, wherein said stationary phase comprises silica functionalized with organic pendants, iii) eluting the mixture loaded in step ii) using an eluent composition comprising a water-soluble organic solvent obtaining eluate fractions, iv) selecting the eluate fractions containing the at least one purified lipoglycopeptide antibiotic. | 2022-06-30 |
20220204552 | MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER - The present disclosure involves optimized methods for production of biologically active proteins termed optimally manufactured stradomers. The present disclosure further provides compositions and methods useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, or infectious diseases. | 2022-06-30 |
20220204553 | METHODS FOR THE FRACTIONATION OF PROTEINS - The present invention provides methods for the fractionation of low molecular weight proteins from mixed protein populations, and proteins obtained by said methods. The methods described herein may find application in, but are not limited to, the detection and/or quantitation of low abundance and/or low molecular weight proteins in biological samples. | 2022-06-30 |
20220204554 | METHOD FOR METAL-FREE PURIFICATION OF PROTEIN FROM A PROTEIN MIXTURE OR A CELL LYSATE WITH THE N-TERMINUS GLYCINE TAGGING - The invention pertains to the method of N-terminus Glycine tagged metal-free protein purification by selective labeling of N-terminus Gly containing proteins, its capture, and release through modified resin under mild operating conditions. The selective labeling of N-terminus Glycine enables the formation of an aminoalcohol. The invention is for selective tagging of N-Gly in a protein. The invention is for separation of immobilised N-terminus glycine proteins from the functionalised resin under mild aqueous physiological conditions by C—C bond dissociation with additive, in which the additive enables the resonance-assisted electron density (RED) polarization to facilitate C—C bond dissociation. The invention provides the N-Gly specific installation of a probe in a protein within cell lysate. The invention covers the special aldehydes, including its on-resin derivative, for the given purpose. | 2022-06-30 |
20220204555 | METHOD FOR PURIFICATION OF PLASMA PROTEINS - The present invention relates to a method for purification of plasma proteins. More closely, the invention relates to a method using magnetic beads for separation of different plasma proteins from a plasma fraction, such as a cryoprecipitate or cryosupernatant of plasma, or alternatively directly from cell culture of recombinant plasma proteins. | 2022-06-30 |
20220204556 | SYSTEMS AND METHODS FOR PROCESS SCALE ISOLATION OF IMMUNOGLOBULIN G - Methods are provided for isolation of immunoglobulin G (IgG) from plasma, where IgG is initially fractioned by salt precipitation, followed by successive ion exchange steps in which IgG appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with IgG collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield. | 2022-06-30 |
20220204557 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES - Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds. | 2022-06-30 |
20220204558 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS - The invention relates to the synthesis of boronic ester and acid compounds. More particularly, the invention provides improved synthetic processes for the large-scale production of boronic ester and acid compounds, including the peptide boronic acid proteasome inhibitor bortezomib. | 2022-06-30 |
20220204559 | SHORT SYNTHETIC PEPTIDES AND THEIR USES FOR TREATING RETINAL DEGENERATIVE DISEASES AND/OR TISSUE INJURIES - Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment of a retinal degenerative disease or tissue injury. Also disclosed herein are methods of treating a retinal degenerative disease or tissue injury, by administering to a subject in need of such treatment, a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure. | 2022-06-30 |
20220204560 | NOVEL OLIGOPEPTIDE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to a novel oligopeptide, and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient. The oligopeptide of the present invention has an advantage in that the molecular weight thereof is less than that of an antibody, and thus the risk of an immune response is low, and it has better tissue permeability. The oligopeptide can exhibit the effect of inhibiting the proliferation of malignant tumors by selectively acting on cancer cells or cancer tissue. | 2022-06-30 |
20220204561 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY - Described herein are methods, compositions, kits and synthetic peptide shuttle agents relating to the transduction of proteinaceous and/or non-proteinaceous cargoes. The method generally comprises contacting target eukaryotic cells with a non-proteinaceous cargo and a concentration of a synthetic peptide shuttle agent sufficient to increase the transduction efficiency of the non-proteinaceous cargo, as compared to in the absence of said synthetic peptide shuttle agent. In embodiments, the non-proteinaceous cargo may be a drug, such as a small molecule drug, for treating a disease. In other embodiments, novel synthetic peptide shuttle agents having transduction activity for proteinaceous and/or non-proteinaceous cargoes are described, as well as the use of propidium iodide or other membrane-impermeable fluorescent DNA intercalating agent as a surrogate cargo for selecting versatile synthetic peptide shuttle agents having transduction activity for both proteinaceous and non-proteinaceous cargoes. | 2022-06-30 |
20220204562 | NOVEL PEPTIDE, COMPOSITIONS AND METHOD FOR DELIVERY OF AGENTS INTO CELLS AND TISSUES - Cell penetrating peptides that target many cells types including cells of the retina and cornea with high efficiency are provided herein. These peptides can be used to deliver cargo molecules across a plasma membrane, without the need for chemical conjugation. Compositions and viral vectors comprising these cell-penetrating peptides are also provided. Methods of using the peptides, compositions and viruses to deliver various agents to target cells and tissues are also provided. | 2022-06-30 |
20220204563 | DELIVERY PEPTIDES AND METHODS OF USING THE SAME - The present invention is directed to a peptide, and methods of using the same such as in the delivery of an agent into a cell, or modification of a cell. | 2022-06-30 |
20220204564 | COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR - Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use. | 2022-06-30 |
20220204565 | Cyclic Peptide Antiviral Agents and Methods Using Same - The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same. | 2022-06-30 |
20220204566 | ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDES - There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
| 2022-06-30 |
20220204567 | RECOMBINANT INFLUENZA ANTIGENS - The invention provides recombinant influenza A hemagglutinin (HA) polypeptides, comprising an HA1 and a HA2 domain of an influenza A virus HA, and comprising an amino acid sequence wherein:
| 2022-06-30 |
20220204568 | METHOD FOR RAPID PREPARATION OF EPIDEMIC INFECTIOUS BRONCHITIS VACCINE - The present disclosure provides a method for rapid preparation of an epidemic infectious bronchitis vaccine. An infectious clone of an infectious bronchitis virus (IBV) H120 vaccine strain is used as a skeleton carrier and an antigen gene in the skeleton carrier is replaced with a target antigen gene of an epidemic infectious bronchitis virus strain, to obtain a recombinant bronchitis virus. The target antigen gene is an S1 gene or an S gene. The S gene is one of the S gene fragments of the epidemic infectious bronchitis virus strain or a fusion gene composed of multiple S gene fragments. Furthermore, the target antigen gene and an N gene can be simultaneously replaced and a signal peptide region of the original S1 gene in the skeleton carrier is retained during the replacement. | 2022-06-30 |
20220204569 | NUCLEIC ACID-BINDING PROTEIN - The present invention provides a novel modified protein which is to be used, as a novel detection tool relating to gene expression, for detecting a chromatin open structure more easily at a higher sensitivity than by the conventional technique. The present invention relates to: a nucleic acid binding fluorescent protein, said protein containing a DNA binding domain in which 3 or more TAL-repeats are repeatedly connected, characterized by binding independently from base sequences; and a method for fluorescent labeling of an open chromatin in a vital cell, said method comprising a step for transferring a gene encoding a nucleic acid binding protein into the vital cell, characterized in that the nucleic acid binding protein is a protein comprising a DNA binding domain, in which 3 or more TAL-repeats are repeatedly connected, and a fluorescent protein directly or indirectly bound thereto and the DNA binding domain binds to a nucleic acid independently from base sequences. | 2022-06-30 |
20220204570 | CRA4S1 GENE, ENCODED CRA4S1 PROTEIN, AND APPLICATION - Provided are a cra4S1 gene, an encoded cra4S1 protein, and a vaccine or drug containing the cra4S1 protein or a fragment thereof. A nucleotide sequence of the cra4S1 gene is represented by SEQ ID NO. 1. The vaccine combines the specific target of an outer membrane protein of | 2022-06-30 |
20220204571 | SYSTEM AND METHOD FOR USING PEPTIDES FOR FLAVORINGS - A method for using peptides for flavorings is described. The method includes, at least, obtaining a microalgae, extracting chlorella protein from the microalgae, modifying a factor associated with the chlorella protein to change an amino acid combination of the chlorella protein, and identifying a peptide flavoring associated with the modified amino acid combination. | 2022-06-30 |
20220204572 | TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9 - The invention provides structurally-constrained peptides by hydrocarbon stapling of a BCL9 HD2 helix for use as a therapeutic agent. The invention further provides methods and kits for use of the structurally-constrained peptide of the instant invention. The invention is based, at least in part, on the results provided herein demonstrating that hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, possess superior pharmacokinetic properties compared to the corresponding unmodified peptides, and are highly effective in binding to β-catenin in vitro, in cellulo, and in vivo, disrupting the BCL9/β-catenin interaction, and thereby interfering with deregulated Wnt/β-catenin signaling for therapeutic benefit in a variety of human diseases including human cancer. | 2022-06-30 |
20220204573 | ICAM-1 TARGETED FUSION ENZYMES - Proteins, nucleic acids encoding the proteins, compositions comprising the proteins, and methods are provided. The proteins have the ability to be self-targeted to ICAM-1 and, if desired, enzymatically-released at acidic pH. The ICAM-1-targeting peptides are provided as single copies or multiples repeats, and can be separated by linkers from the enzyme segment, from which the ICAM-1 targeting peptides can be released, if desired, at acidic pH. These fusion proteins enhance the activity of the enzyme segment within or liberated from the fusion protein, and provide increased recognition and targeting of diseased organs, transport from the bloodstream across the endothelium into said diseased organ, and intracellular uptake and lysosomal trafficking by cells in them, both in peripheral tissues and the central nervous system. Representative nucleotide and amino acid sequences of these fusion proteins, as well as in vitro, cellular, and in vivo animal data are provided. The described proteins can be used as a protein therapy, a gene therapy, or an implanted cell therapy. | 2022-06-30 |
20220204574 | PRODUCTION OF LARGE-SIZED QUASIDYSTROPHINS USING OVERLAPPING AAV VECTORS - The present invention concerns a quasidystrophin (QD) having the structure CH1CH2H1R1R2R3H2R8R9 in its N-terminal part and advantageously further comprising the R16 and R17 rod domains, as well as the dual AAV vector system which allows producing it. | 2022-06-30 |
20220204575 | MODULATING SURVIVAL OF THERAPEUTIC CELLS AND METHODS, CELLS AND NUCLEIC ACIDS RELATED THERETO - Provided are methods of modulating the survival of therapeutic cells as well as cells and nucleic acids and vectors useful in such methods. Such survival modulation may include enhancing survival and/or enhancing death of the therapeutic cells. The provided methods include administering a therapeutic cell, nucleic acid and/or vector to a subject, the administered therapeutic cells, nucleic acids and/or vectors including one or more heterologous apoptosis modulating agents and/or one or more encoding sequences thereof. Cells of the disclosure include or encode one or more heterologous apoptosis modulating agents. | 2022-06-30 |
20220204576 | ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2022-06-30 |
20220204577 | Synthetic Peptides With Affinity for the Interleukin-10 Receptor, Pharmaceutical Composition and Use Thereof as Immunomodulators for Treating Autoimmune, Inflammatory or Allergic Diseases - This invention refers to the selection and characterization of synthetic peptides that have affinity for immune system cells receptors, particularly affinity to the Interleukin-10 (IL-10) receptor, as well as pharmaceutical compositions, and use of these peptides to prepare drugs or immunogenic compounds. These synthetic peptides can bind to cell receptors and promote important regulatory profiles for the treatment and/or prophylaxis of diseases where there is an immune disorder, especially when the diseases related to the immune disorder are: chronic or acute inflammatory diseases, allergic and/or autoimmune. | 2022-06-30 |
20220204578 | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 - Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response. | 2022-06-30 |
20220204579 | METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USES - The present invention is a DNA expression vector comprising: a toxP: a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention. | 2022-06-30 |
20220204580 | POLYPEPTIDES AND USES THEREOF - Disclosed are polypeptides which are pramlintide analogues and uses thereof. In particular, the present invention relates to polypeptides of SEQ ID NO 2 which are pramlintide analogues conjugated to half-life extending moieties such as albumin binding moieties and uses thereof. | 2022-06-30 |
20220204581 | MONOMERIC PEPTIDE MULTI-AGONIST TARGETING THE GLP1 RECEPTOR AND NPY RECEPTORS - A series of chimeric peptides that provide a mechanism for obesity treatment concomitant with T2DM in the form of dual agonism of the anorectic neuropeptide Y-receptor (Y2-R) and the glucoregulatory receptor GLP1-R. Preliminary results show that, dependent on the selected peptide, once-daily administration suppress FI in male and female rats can be reduced to 12-65% compared to baseline conditions before treatment, dependent on dose and age of animals, and glucose tolerance can be improved as well. Peptides also demonstrated Y1-receptor agonism, conferring protection on beta-islet cells against inflammatory damage. The peptides were designed by targeting serial anorectic pathways simultaneously and are promising candidates for modulating FI and glucoregulation in an efficacious and safe way. | 2022-06-30 |
20220204582 | SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF - The disclosure provides synthetic immune receptors (SIRs), nucleic acids encoding the SIRs, methods of making and using the SIRs, in, for example, adoptive cell therapy. | 2022-06-30 |
20220204583 | VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET THE BLOOD BRAIN BARRIER AND METHODS OF USE - The present disclosure provides isolated polypeptides comprising variable lymphocyte receptors that specifically bind the blood brain barrier, compositions, and methods of use. | 2022-06-30 |
20220204584 | HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS - Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. | 2022-06-30 |
20220204585 | Reagents and Assays using Modified Integrin Domains - Modified integrin polypeptides are provided. Methods of identifying binding agents that bind to a modified integrin polypeptide are also provided. | 2022-06-30 |
20220204586 | SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF - SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof. | 2022-06-30 |
20220204587 | TGF-B-RECEPTOR ECTODOMAIN FUSION MOLECULES AND USES THEREOF - The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-β) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules. | 2022-06-30 |
20220204588 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 2022-06-30 |
20220204589 | SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS - The present invention relates to polypeptides which include tenth fibronectin type III domains ( | 2022-06-30 |
20220204590 | Antibody-based blockage of SARS-CoV-2-specific furin cleavage site - The present invention provides an antibody and its use method for immunologically blocking furin cleavage site on the S1/S2 boundary of SARS-CoV-2 spike protein that are in purified form or from a biological sample to prevent the SARS-CoV-2 spike protein cleavage caused by furin and furin-related proteases. | 2022-06-30 |
20220204591 | ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF - Provided herein are modified anti-SARS-COV-2 antibodies or antigen binding fragments thereof having extended half life and optimized immune activities. Disclosed herein is also directed to pharmaceutical compositions comprising the same and a method for treating or preventing a disease in human patients that is caused by or related to the infection of SARS-COV-2. | 2022-06-30 |
20220204592 | HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 2022-06-30 |
20220204593 | DOSAGE REGIMENS FOR AND COMPOSITIONS INCLUDING ANTI-RSV ANTIBODIES - In one aspect, this disclosure describes methods of treating or preventing RSV infection in a patient in need thereof. The methods including dosing regimens for administering a composition including a fixed dose of an anti-RSV monoclonal antibody or an antigen binding fragment thereof. In another aspect, this disclosure describes pharmaceutical compositions for the treatment or prevention of RSV infection. In yet another aspect, this disclosure describes a pharmaceutical unit dose including nirsevimab. | 2022-06-30 |
20220204594 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS - This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics. | 2022-06-30 |
20220204595 | ANTIBODY MOLECULES AND USES THEREOF - This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from | 2022-06-30 |
20220204596 | ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME - The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described. | 2022-06-30 |
20220204597 | FORMULATIONS OF MONOCLONAL ANTIBODIES - The present invention provides a formulation comprising: (i) a monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater (e.g. about 50 mg/ml to about 200 mg/ml) and the ionic excipient is present at a concentration of about 50 to about 150 mM and the formulation has a pH of 5.5 to 6.5. | 2022-06-30 |
20220204598 | COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTS - The present disclosure provides humanized antibodies and antigen-binding fragments thereof that specifically bind to SFRP2 and compositions comprising such humanized antibodies or antigen-binding fragments thereof. In some aspects, the humanized antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased SFRP2, such as cancer. In some aspects, the antibodies or antigen-binding fragments can be used to treat osteosarcoma. | 2022-06-30 |
20220204599 | NOVEL CTHRC1-SPECIFIC ANTIBODY AND USE THEREOF - The present invention relates to a novel antibody which binds to CTHRC1 and use thereof. | 2022-06-30 |
20220204600 | THERAPEUTIC PROTEIN FORMULATIONS COMPRISING ANTI-DNABII ANTIBODIES AND USES THEREOF - The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg/mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exarcebations of chronic obstructive pulmonary disease or chronic bronchitis are also provided. | 2022-06-30 |
20220204601 | ANTI-TAU ANTIBODY AND USE OF SAME - An anti-tau antibody according to the present invention specifically binds to a tau protein, in which the 280 | 2022-06-30 |
20220204602 | BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND FACTOR H FUSION PROTEINS AND USES THEREOF - This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof. | 2022-06-30 |
20220204603 | ANTI-ANG2 ANTIBODY AND USE THEREOF - The present disclosure relates to an antibody to inhibit function of Angiopoietin-2 (Ang-2) by binding specifically to Ang-2, and directed to an anti-Ang2 antibody, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method of preparing the same, an angiogenesis inhibitor comprising the same, a composition for treating a disease related with Angiopoietin-2 activation and/or overproduction, a composition for diagnosing a disease related with Angiopoietin-2 activation and/or overproduction, a composition for treating eye disease or a composition for preventing or treating a cancer, and a composition for combining an antibody binding to Ang2 with a drug other than the antibody binding to Ang2. | 2022-06-30 |
20220204604 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Provided herein are methods and compositions for treating cancer or a tumor in a subject by administering to the subject a first agent that disrupts the interaction between PD-L2/RGMb and a second agent that disrupts the interaction between PD-1/PD-L1. The subject may have dysbiosis and/or be nonresponsive to immune checkpoint therapy. | 2022-06-30 |
20220204605 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE - The objective of the invention is to provide cross-species anti-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1. To obtain the anti-latent TGF-beta 1 antibodies of the invention, anti-latent-latent TGF-beta 1 antibodies which inhibit a protease mediated activation of latent TGF-beta 1 without inhibiting integrin mediated activation of latent TGF-beta 1 were screened, and then humanized, and further optimized. The invention also provides combination therapies comprising an anti-latent TGF-beta 1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonists. | 2022-06-30 |
20220204606 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF - The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases. | 2022-06-30 |
20220204607 | Production of Biosimilar Ustekinumab In CHO Cells - The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease. | 2022-06-30 |
20220204608 | THERAPEUTIC AGENT FOR UROLOGICAL CANCER WHICH IS CHARACTERIZED BY BEING ADMINISTERED WITH IL-6 INHIBITOR AND CCR2 INHIBITOR IN COMBINATION - Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided. | 2022-06-30 |
20220204609 | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR WHICH TARGETS CLAUDIN 18.2 - Disclosed are an antibody or an antigen binding fragment or chimeric antigen receptor thereof which binds to Claudin18.2, and a preparation method and a use. The chimeric antigen receptor sequentially comprises the antibody or the antigen binding fragment thereof which binds to the Claudin18.2 antigen, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The antibody or the antigen binding fragment or chimeric antigen receptor thereof has stronger affinity and killing capability for cells secreting Claudin18.2, and a better tumor inhibiting effects. | 2022-06-30 |
20220204610 | PROTEIN BINDERS FOR IRHOM2 - The present invention relates to a protein binder that binds to human iRhom2, and inhibits and/or reduces TACE/ADAM17 activity when bound to human iRhom2. | 2022-06-30 |
20220204611 | TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF - The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described. | 2022-06-30 |
20220204612 | Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof - The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided. | 2022-06-30 |
20220204613 | ANTI-CD47 ANTIBODIES AND USES THEREOF - Provided herein are anti-CD47 antibodies and antigen-binding portions thereof and methods for using the same. | 2022-06-30 |
20220204614 | HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAME - The present invention relates to a humanized antibody specific for CD22 and a chimeric antigen receptor using the same, and more specifically, to a humanized antibody specifically binding to CD22, a chimeric antigen receptor including the antibody or a CD19xCD22 antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition including the same for preventing or treating a disease mediated by B cells. | 2022-06-30 |
20220204615 | Caninized Antibodies - The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs. | 2022-06-30 |
20220204616 | HUMANIZED ANTI-HUMAN CD19 ANTIBODIES AND METHODS OF USE - Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same. | 2022-06-30 |
20220204617 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE - Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular the use of VIB551, a humanised, affinity-optimised, afucosylated IgG1 kappa monoclonal antibody to treat Neuromyelitis optica spectrum disorder. | 2022-06-30 |
20220204618 | ANTI-NKG2A ANTIBODIES AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided. | 2022-06-30 |
20220204619 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19 - The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells. | 2022-06-30 |
20220204620 | MEANS AND METHODS FOR TREATING BURKITT LYMPHOMA OR LEUKEMIA - The present invention relates to a method of treating Burkitt lymphoma or leukemia in a patient, the method comprising administering to said patient a composition comprising a CD19×CD3 bispecific antibody in at least one treatment cycle, wherein the treatment cycle comprises administering a first dose of 15 μg/m | 2022-06-30 |
20220204621 | BISPECIFIC ANTIBODIES TO ROR1 AND CD3 - There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer. | 2022-06-30 |